Nearly two

1:17FormerPresidentDonaldTrumparrivesatRonaldReaganWashingtonNationalAirport,Aug.3,2023,inArlington, SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We




comprehensive

author：leisure time    Page View：37

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

advertisement

Featured Speakers

  • Irena Melnikova, Ph.D., partner, Pfizer Ventures
  • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
  • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： What it’s like to watch children die of measles
Next article： BioMarin wins approval for gene therapy to treat hemophilia A